Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
7.31Last Year’s EPS
5.85Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: 2.05%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with record revenue growth and strategic investments in pipeline expansion and capital allocation. Despite facing challenges in xenotransplantation and an increasingly competitive landscape, the company remains confident in sustained double-digit growth and product portfolio strength.Company Guidance
During the first quarter of 2025, United Therapeutics Corporation reported a record revenue of $794 million, marking a 17% growth from the same period in 2024. This achievement represents the ninth record revenue quarter out of the past twelve, driven by robust performance across their treprostinil products, including Tyvaso, Orenitram, Remodulin, and Unituxin, which have maintained double-digit growth for 11 consecutive quarters. The company continues to focus on its innovation pipeline, with five registration phase studies underway and a pending marketing application at the FDA, alongside several new preclinical candidates. Despite the increased competition in the PAH market, United Therapeutics remains optimistic about sustaining its growth trajectory due to their strategic capital allocation, strict financial discipline, and strong commercial execution.Record Revenue Quarter
United Therapeutics reported a record revenue of $794 million for the first quarter of 2025, representing a 17% growth from the same quarter in 2024, marking the 9th record revenue quarter out of the last 12.
Strong Product Portfolio Performance
Double-digit revenue growth was driven by robust results for treprostinil products, including Tyvaso, Orenitram, Remodulin, and Unituxin, with Tyvaso DPI positioned for sustained long-term growth.
Expansion and Capital Allocation
Significant investments in new manufacturing facilities and acquisitions, such as IVIVA and Miromatrix, were made to enhance organ alternative development expertise, alongside a $1 billion share repurchase program.
Positive Regulatory Feedback
Positive FDA feedback on the UTHYMOKIDNEY program allows for IND submissions without additional Baboon clinical studies, advancing the pipeline's registration phase studies and clinical trials.
---
UTHR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
UTHR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 30, 2025 | $300.76 | $303.09 | +0.77% |
| Feb 26, 2025 | $357.50 | $318.89 | -10.80% |
| Oct 30, 2024 | $352.80 | $361.40 | +2.44% |
| Jul 31, 2024 | $337.54 | $313.29 | -7.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does United Therapeutics (UTHR) report earnings?
United Therapeutics (UTHR) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is United Therapeutics (UTHR) earnings time?
United Therapeutics (UTHR) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is UTHR EPS forecast?
UTHR EPS forecast for the fiscal quarter 2025 (Q2) is 7.31.
---